The Annual IAS-USA DC Virtual Course: Update on HIV Medicine Emerging Challenges

The Annual IAS-USA DC Virtual Course: Update on HIV Medicine Emerging Challenges

Registration Details

  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Tuesday, December 3, 2024
  • Virtual Fellows: $15.00 (USD)
  • Virtual Fellows ends: Tuesday, December 3, 2024


Henry Masur, MD
George Washington University
Washington DC
Michael S. Saag, MD
University of Alabama at Birmingham


Ellen F. Eaton, MD
University of Alabama at Birmingham
Birmingham, AL
Rajesh T. Gandhi, MD
Harvard University
Boston, MA
Roy M. Gulick, MD, MPH
Weill Cornell Medicine
New York, NY
Priscilla Y. Hsue, MD
University of California San Francisco
San Francisco, CA
Timothy J. Wilkin, MD, MPH
University of California San Diego
San Diego, California

December 3, 2024

11:00 AM - 3:30 PM ET



Program Description

This comprehensive half-day virtual course will explore emerging challenges in HIV medicine. This course will delve into the management of substance use disorder (SUD) beyond opioids, including the potential use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to treat addiction; review the latest guidelines on screening for and treatment of anal cancer, a human papillomavirus (HPV)-related condition; and discuss the implementation of long-acting drugs for both HIV treatment and prevention, including new medications currently in development and in clinical trials. Other key topics include strategies to reduce cardiovascular disease risk in people with HIV and updates on antiretroviral therapy guidelines.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and other emerging challenges in HIV medicine. Information will be presented through a mix of didactic lectures, clinically relevant cases, and discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Summarize the latest guidelines for screening for and treatment of HPV and anal cancer in individuals at risk
  • Initiate treatment for SUD beyond opioids, including stimulants in patients with HIV
  • Describe the potential use of GLP-1 RAs in people with HIV
  • Describe the available data supporting the use of long-acting drugs for the treatment and prevention of HIV, including recent clinical trials of new antiretroviral drugs in development for treatment of HIV and their potential role(s) in future clinical practice
  • Summarize the latest guidelines and recommendations for reducing cardiovascular disease risk in people with HIV
  • List key updates in the latest antiretroviral therapy and prevention guidelines
  • Describe the most current data on currently available and newly available antiretroviral drugs and approaches


  • SUD beyond opioids, including the potential use GLP-1 RAs for addiction
  • HPV, anal cancer, and updates on the guidelines on how to screen and treat
  • Long-acting drugs for treatment and prevention of HIV, including new drugs
  • Reducing the risk of cardiovascular disease in people with HIV
  • Updates on the latest guidelines for the treatment and prevention of HIV infection in adults

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.